Sep 26, 2023 / 03:40PM GMT
Kristen Kluska - Cantor Fitzgerald & Co. - Analyst
Okay, great. Good morning, everybody. For our next presentation. I'm joined by Rohan Palekar, the CEO of 89bio. Welcome to our conference.
Rohan Palekar - 89bio, Inc. - CEO
Thanks Kristen. [Great to be here.]
Questions and Answers:
Kristen Kluska - Cantor Fitzgerald & Co. - AnalystAwesome. So the last 12 months have been one of the most exciting times for investors focusing on the NASH space. We went from seeing a few disappointing trial results to now having a few positive ones, yourself included. And are one step closer towards a first potential approval. So why do you think now more than ever investors should focus their time on this space?
Rohan Palekar - 89bio, Inc. - CEO
Kristen, (technical difficulty) the last 12 months, I think at NASH has been pretty transformational, had a little time period where you had a bunch of trial results which came out negative. And then in the last 12 months, including
Trustpilot
